Editas EDIT-401 achieves ~90% reductions in LDL-C, Lp(a), ApoB in primates

Editas Medicine presented preclinical data showing EDIT-401 achieved robust ~90% mean reductions in multiple atherogenic lipoproteins in non-human primates with a single dose. The company plans to submit a CTN by mid-2026 and achieve early human proof-of-concept data by end of 2026, advancing its lead gene-editing candidate for hyperlipidemia treatment.